HOPKINTON, Mass., Jan. 14 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. today announced revenue results for the fourth quarter and full year ended December 31, 2009, and its expected year-end cash position, based upon management's review of preliminary financial information.
The Company expects to report cash, cash equivalents and marketable securities of approximately $38 million and outstanding short-term borrowings of approximately $15 million as of December 31, 2009. In addition, the Company announced that it expects to report positive operating cash flows on a full-year basis for 2009, one year ahead of previous guidance.
Statement Regarding Use of Non-GAAP Financial Measures
Caliper supplements its GAAP financial reporting with certain non-GAAP financial measures. Non-GAAP revenue in this press release excludes the impact of revenue from business operations which were divested in the fourth quarters of 2008 and 2009, respectively. Caliper believes that providing this additional information enhances investors' understanding of the financial performance of Caliper's operations and increases the comparability of its current financial statements to prior periods.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
Caliper, IVIS and LabChip are registered trademarks of Caliper Life Sciences, Inc.
Non-GAAP Revenues for the Three and Twelve Months Ended December 31, 2009
(1) Divested business operations include the sale of the PDQ and AutoTrace product lines in the fourth quarter of 2008 and the sale of the Xenogen Biosciences business in the fourth quarter of 2009.
Caliper Life Sciences, Inc.
